目的探究2019—2022年自贡地区急性冠心病死亡特征及疾病负担变化,为急性冠心病的防治提供相关依据。方法收集2019年1月至2022年12月自贡市户籍居民急性冠心病的死亡数据,计算死亡率、早死损失寿命年(Years of life lost,YLL)率和伤残...目的探究2019—2022年自贡地区急性冠心病死亡特征及疾病负担变化,为急性冠心病的防治提供相关依据。方法收集2019年1月至2022年12月自贡市户籍居民急性冠心病的死亡数据,计算死亡率、早死损失寿命年(Years of life lost,YLL)率和伤残所致的健康寿命损失年(Years lived with disability,YLD)率,采用年度变化百分比(Annual percentage change,APC)比较率的趋势变化。结果2019年、2022年自贡地区急性冠心病死亡率分别为58.57/10万、62.03/10万,年平均增长4.44%(3.2%~6.02%),其变化趋势有统计学意义(P<0.05),且男性死亡率高于女性。急性冠心病死亡率随着年龄的增大而上升,尤其是45岁以上年龄组死亡率快速上升。YLL率由16.51‰增加到26.88‰,年平均增长5.10%(3.92%~6.28%),YLD率由33.16‰增加至36.18‰,年平均增长4.20%(3.04%~5.30%),变化趋势有统计学意义(P<0.05),且男性YLL率与YLD率均高于女性,年平均增加幅度也高于女性。结论2019—2022年自贡地区急性冠心病死亡率、YLL率和YLD率呈增长趋势,对该地区患病人群造成一定的疾病负担。在急性冠心病死亡事件中,男性和45岁以上的人群显示为需重点关注的高风险人群。展开更多
Infliximab is a potent anti-TNF antibody, which is used with great success in Crohn’s disease patients. Since its release in clinical practice, several adverse reactions have been observed. The interest in possible c...Infliximab is a potent anti-TNF antibody, which is used with great success in Crohn’s disease patients. Since its release in clinical practice, several adverse reactions have been observed. The interest in possible consequences of its administration is still high because of the recent introduction of the drug for the long-term maintenance therapy of refractory luminal and fistulizing Crohn’s disease. We present a case of acute coronary syndrome (non-STEMI) in a patient with corticoid resistant Crohn’s disease after his first dose of infliximab. By reviewing the scant articles that exist in the literature on this topic we made an effort to delineate the possible mechanisms of this phenomenon.展开更多
文摘目的探究2019—2022年自贡地区急性冠心病死亡特征及疾病负担变化,为急性冠心病的防治提供相关依据。方法收集2019年1月至2022年12月自贡市户籍居民急性冠心病的死亡数据,计算死亡率、早死损失寿命年(Years of life lost,YLL)率和伤残所致的健康寿命损失年(Years lived with disability,YLD)率,采用年度变化百分比(Annual percentage change,APC)比较率的趋势变化。结果2019年、2022年自贡地区急性冠心病死亡率分别为58.57/10万、62.03/10万,年平均增长4.44%(3.2%~6.02%),其变化趋势有统计学意义(P<0.05),且男性死亡率高于女性。急性冠心病死亡率随着年龄的增大而上升,尤其是45岁以上年龄组死亡率快速上升。YLL率由16.51‰增加到26.88‰,年平均增长5.10%(3.92%~6.28%),YLD率由33.16‰增加至36.18‰,年平均增长4.20%(3.04%~5.30%),变化趋势有统计学意义(P<0.05),且男性YLL率与YLD率均高于女性,年平均增加幅度也高于女性。结论2019—2022年自贡地区急性冠心病死亡率、YLL率和YLD率呈增长趋势,对该地区患病人群造成一定的疾病负担。在急性冠心病死亡事件中,男性和45岁以上的人群显示为需重点关注的高风险人群。
文摘Infliximab is a potent anti-TNF antibody, which is used with great success in Crohn’s disease patients. Since its release in clinical practice, several adverse reactions have been observed. The interest in possible consequences of its administration is still high because of the recent introduction of the drug for the long-term maintenance therapy of refractory luminal and fistulizing Crohn’s disease. We present a case of acute coronary syndrome (non-STEMI) in a patient with corticoid resistant Crohn’s disease after his first dose of infliximab. By reviewing the scant articles that exist in the literature on this topic we made an effort to delineate the possible mechanisms of this phenomenon.
